Fosamax and Osteonecrosis of the Jaw: Medical Literature on Causation and Risk

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Health Information and Transition to Occupational Risk

This domain has historically provided accessible, structured health and science information to a general audience, drawing from authoritative public data sources such as CDC health alerts and hospital safety reports. The focus has been on broad awareness of medical conditions and preventive measures. Transitioning from this general health context, the focus now narrows to a specific, clinically significant concern: the association between Fosamax exposure and the risk of osteonecrosis of the jaw (ONJ). This pivot moves from population-level health education toward a more targeted occupational exposure inquiry. In mass production environments, where workers may handle or be exposed to bisphosphonate compounds like Fosamax during manufacturing, packaging, or quality control, the potential for unintended exposure warrants careful examination. The shift from general health literacy to occupational risk assessment requires a neutral, evidence-informed approach that prioritizes worker safety without delving into mechanistic claims. This transition acknowledges the legacy of data-driven health communication while addressing a concrete exposure scenario relevant to industrial hygiene and regulatory compliance.

Fosamax: Pharmacology and Recognized Adverse Effects

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its pharmacological action involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a recognized adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the oral cavity, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ involves areas of exposed bone in the mandible or maxilla that persist for more than eight weeks, often accompanied by pain, swelling, and infection. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to assess bone involvement. The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Risk Factors for ONJ

Mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast-mediated bone remodeling. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress osteoclast activity. This suppression can impair the normal repair and remodeling processes that maintain oral bone health, especially after dental procedures or in the presence of infection. Multiscale characterization of jawbone tissue has provided insights into how the jawbone's unique structure and cellular composition may predispose it to complications from bisphosphonate therapy, including ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The reduced bone turnover can lead to microdamage accumulation and compromised healing, creating conditions that favor necrosis. Risk factors for developing ONJ while on Fosamax include invasive dental procedures such as tooth extraction, dental implants, or boney surgery; diagnosis of cancer; concomitant therapies like chemotherapy, corticosteroids, or angiogenesis inhibitors; poor oral hygiene; and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings, Causation, and Epidemiological Evidence

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. The label notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and lists known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56, https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This may create ambiguity regarding the strength of the association, as clinical trial data did not show a significant difference in symptom rates, yet post-marketing reports have identified ONJ cases. Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and the development of ONJ. The time to onset of symptoms after starting the drug can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after stopping the medication, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal link, as symptoms appear after exposure, resolve upon discontinuation, and recur with re-exposure. Additionally, epidemiological data from a cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use, with absolute risks remaining low (~0.05% after 5 years) and diminishing after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This dose-response relationship, where longer exposure increases risk, further supports causation.

Timeline, Management, and Summary of Risk

The timeline between exposure and documented harm is variable. Symptoms can appear as early as one day after starting Fosamax, but more commonly develop over months to years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with duration of bisphosphonate therapy, as noted in both the prescribing information and epidemiological studies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1, https://pubmed.ncbi.nlm.nih.gov/39400702/). For patients who develop ONJ, the condition can be challenging to manage, and treatment often involves discontinuation of the bisphosphonate, oral antimicrobial rinses, and, in some cases, surgical debridement. The risk diminishes after stopping the drug, but the bone remodeling suppression may persist for years due to the long half-life of bisphosphonates in bone. In summary, Fosamax is associated with an increased risk of osteonecrosis of the jaw, particularly with longer duration of use and in the presence of known risk factors such as invasive dental procedures. The prescribing information provides warnings about this adverse effect, but clinical trial data show similar symptom rates between Fosamax and placebo, which may complicate risk communication. Causation is supported by temporal patterns of symptom onset, resolution upon discontinuation, recurrence with rechallenge, and epidemiological evidence of a dose-response relationship. Patients and healthcare providers should weigh the benefits of Fosamax for fracture prevention against the low but real risk of ONJ, especially when considering long-term therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ) and how is it related to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the oral cavity, often associated with tooth extraction or local infection. Fosamax (alendronate), a bisphosphonate, has been reported to increase the risk of ONJ, particularly with long-term use and in the presence of risk factors such as invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders like periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures. Longer duration of bisphosphonate exposure also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Is there evidence supporting a causal link between Fosamax and ONJ?

Yes, causation is supported by temporal patterns: symptoms appear after exposure, resolve upon discontinuation, and recur with rechallenge. Epidemiological studies show a dose-response relationship, with ONJ risk increasing with longer treatment duration (e.g., threefold after 2-3 years, eightfold after 10 years) (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.